Professor Andreas Meyer-Lindenberg, MD, MSc, MBA
Prof. Meyer-Lindenberg is Director of the Central Institute of Mental Health and Head of the Executive Board, as well as the Medical Director of the Department of Psychiatry and Psychotherapy at the Institute, based in Mannheim, Germany, and Professor and Chairman of Psychiatry and Psychotherapy at the University of Heidelberg in Heidelberg, Germany. He is board certified in psychiatry, psychotherapy, and neurology. Before coming to Mannheim in 2007, he spent ten years as a scientist at the National Institutes of Mental Health, Bethesda, USA.
Prof. Meyer-Lindenberg is the author of more than 480 peer-reviewed articles and book chapters in journals such as Nature, Science, Nature Neuroscience, Nature Medicine, Nature Reviews Neuroscience, Nature Genetics, Neuron, PNAS, and others. He has been continuously named as one of the most highly cited scientists in the world. He is the Editor-in-Chief of the ECNP Journal Neuroscience Applied, associate editor of Science Advances and on the editorial board of a number of other journals such as Schizophrenia Bulletin, European Neuropsycho-pharmacology, Psychiatry Research: Neuroimaging, and Neuroimage. He has been principal investigator in several large national and international studies on innovative biological treatments for schizophrenia.
His research interests focus on the development of novel treatments for severe psychiatric disorders, especially schizophrenia, through an application of multimodal neuroimaging, genetics and enviromics to characterize brain circuits underlying the risk for mental illness and cognitive dysfunction.
In recognition of his research, Prof. Meyer-Lindenberg has received awards throughout his career, including: Bristol-Myers-Squibb Young Investigator Award (1998), NIH Award for Excellence in Biomedical Research (1999, 2000, 2001), NARSAD Young Investigator Award (2000), Department of Health and Human Services Secretary’s Award for Distinguished Service (2006), Roche/Nature Medicine Award for Translational Neuroscience (2006), the Joel Elkes International Award for Clinical Research from the American College of Neuropsychopharmacology (2006), A.E. Bennett Award of the Society for Biological Psychiatry (2007), NARSAD Distinguished Investigator Award (2009), Kurt Schneider Scientific Award (2010), the Hans-Jörg Weitbrecht-Preis für Klinische Neurowissenschaften (2011), the ECNP Neuropsychopharmacology Award (2012), the Prix ROGER DE SPOELBERCH (2014), and the 2016 CINP Lilly Neuroscience Clinical Research Award.
10 selected peer-reviewed publications
*shared first authorship
+shared corresponding authorship
Total external funding volume (personal contribution only if participant, total grant if coordinator/lead PI): > 69.4 Mio € ( DFG, European Union, BMBF, MWK, Klaus Tschira-Foundation, Hans Werner Hector Foundation, Foundation Roger de Spoelberch, Federal Innovations Fond etc.).
Grants: Telethon Foundation, Guggenheim Foundation, Academy of Finland Research Council Swiss National Science Foundation, Wellcome Trust, Medical Research Council, National Science Foundation USA, Deutsche Forschungsgemeinschaft (DFG), NIH, Austrian Science Foundation, European Research council, others
Peer reviewed publications: >470 (May 2022) h-index: 119 (Google Scholar, May 5, 2022)
i10-index: 382 (Google Scholar, May 5, 2022)
annual citations: 4.983 (in 2020), 6.228 (in 2021) (Google Scholar, May, 2022)
total citations: 55.792 (all), 26.922 (since 2017) (Google Scholar, May 05, 2022)
impact factor: > 3.252 (December 2020)
RG Score: 53.6 (Researchgate, January 18, 2022)
ORCID ID: orcid.org/0000-0001-5619-1123
Highly cited researcher (Clarivate Analytics, formerly: Thomson Reuters), 2014-2021
XXVII Congresso Nazionale della Società Italiana di Psicopatologia
Giovedì 23 febbraio 2023
LEPTIS MAGNA 2
LETTURA MAGISTRALE – PERSONALIZZAZIONE (SESSIONE ACCREDITATA ECM)
Biomarkers and personalised care for mental disorders